Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: NOW stock price vs CVS: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CVS's multiple
Needs CVS P/E.
Implied fair value · at NOW's multiple
Needs NOW P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
16 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ServiceNow, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
CVS HEALTH CORPORATION · implied price per share
Bear
$43.35
Base
$58.49
Bull
$78.21
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
MICROSOFT CORP
NOW vs MSFT
ADOBE INC.
NOW vs ADBE
ORACLE CORP
NOW vs ORCL
Salesforce, Inc.
NOW vs CRM
INTERNATIONAL BUSINESS MACHINES CORP
NOW vs IBM
Paycom Software, Inc.
NOW vs PAYC
Walgreens Boots Alliance, Inc.
NOW vs WBA
UNITEDHEALTH GROUP INC
NOW vs UNH
Walmart Inc.
NOW vs WMT
Cigna Group
NOW vs CI
HUMANA INC
NOW vs HUM
Elevance Health, Inc.
NOW vs ELV
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Edwyn research
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe NOW can sustain its 20.9% revenue growth and 77.5% gross margin profile, then a cautious buy/hold makes sense because CVS-implied P/E suggests 12.8% upside and NOW’s capital efficiency is far superior to CVS.
On the provided P/E framework, NOW appears modestly undervalued versus CVS-implied price, with implied price of $125.47 versus current price of $111.23, or 12.8% upside. However, the broader valuation signals are mixed because the DCF range of $18.15-$24.56 is far below the market price, while the historical band of $100.11-$122.35 suggests NOW is already near the upper end of its recent trading range.
Supporting Metrics
